Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 1081 to 1090 of 1090 total matches.
Pravastatin And Simvastatin for Hypercholesterolemia
The Medical Letter on Drugs and Therapeutics • Mar 08, 1991 (Issue 839)
COPYRIGHT LAWS
Cost of simvastatin cyclosporine erythromycin Gemfibrozil Interactions drug Cost ...
Pravastatin (Pravachol - Bristol-Myers Squibb) and simvastatin (Zocor - Merck), two new inhibitors of cholesterol synthesis similar to lovastatin (Mevacor - Merck), have been marketed in Canada and several European countries and may soon be available in the USA for treatment of high plasma cholesterol concentrations. Drugs already marketed here for this indication were recently reviewed in The Medical Letter (Volume 33, page 1, January 11, 1991).
Rosiglitazone for Type 2 Diabetes Mellitus
The Medical Letter on Drugs and Therapeutics • Aug 13, 1999 (Issue 1059)
heart failure has not been established. Clinically important interactions with other drugs ...
Rosiglitazone, the second thiazolidinedione derivative to be marketed in the USA for treatment of type 2 diabetes, has been approved by the FDA for use either alone or combined with meformin.
Gamma Hydroxybutyrate (Xyrem) for Narcolepsy
The Medical Letter on Drugs and Therapeutics • Dec 09, 2002 (Issue 1145)
The Medical Letter
On Drugs and Therapeutics
www.medicalletter.org
Published by The Medical ...
The FDA has approved use of gamma hydroxybutyrate (sodium oxybate is the official generic name; Xyrem - Orphan Medical) for oral treatment of cataplexy in patients with narcolepsy. Gamma hydroxybutyrate (GHB), a metabolite of gamma-aminobutyric acid (GABA), is a central-nervous-system depressant marketed in Europe for use in general anesthesia. In recent years it has been notorious for its use in "date-rape" (Medical Letter 2002; 44:21). Xyrem is a Schedule III controlled substance.
Transdermal Selegiline (Emsam)
The Medical Letter on Drugs and Therapeutics • May 22, 2006 (Issue 1235)
Letter
®
On Drugs and Therapeutics
Transdermal Selegiline (Emsam)
Volume 48 (Issue 1235)
May 22 ...
The FDA recently approved the monoamine oxidase inhibitor (MAOI) selegiline in a transdermal (patch) formulation (Emsam - Bristol-Myers Squibb/Somerset) for treatment of major depressive disorder. Selegiline is also available in an oral formulation (Eldepryl, and others) for treatment of Parkinson's disease.
Ropinirole for Restless Legs Syndrome
The Medical Letter on Drugs and Therapeutics • Aug 01, 2005 (Issue 1214)
Letter
®
On Drugs and Therapeutics
IN THIS ISSUE
Volume 47 (Issue 1214)
August 1, 2005 ...
Ropinirole (Requip - GlaxoSmithKline), a dopamine agonist already available for treatment of Parkinson's disease, is now the first drug approved by the FDA for treatment of moderate to severe restless legs syndrome (RLS).
Pitolisant (Wakix) for Narcolepsy
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021 (Issue 1617)
in patients with narcolepsy.
Not a controlled substance, unlike other drugs approved for
these indications ...
The FDA has approved pitolisant (Wakix – Harmony), a histamine-3 (H3)-receptor antagonist/inverse agonist, for treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy. It is the first H3-receptor antagonist/inverse agonist to become available in the US and the first non-controlled substance to receive FDA approval for these indications. Pitolisant has been available in Europe since 2016.
Nivolumab (Opdivo) for Metastatic Melanoma and Metastatic NSCLC
The Medical Letter on Drugs and Therapeutics • Jun 08, 2015 (Issue 1470)
The Medical Letter®
on Drugs and Therapeutics
Objective Drug Reviews Since 1959
Volume 57 (Issue ...
The FDA has approved nivolumab (Opdivo – BMS),
an IV programmed death receptor-1 (PD-1) blocking
antibody, for treatment of unresectable or metastatic
melanoma that has progressed following treatment
with ipilimumab (and a BRAF inhibitor in patients who
are BRAF V600 mutation positive) and for treatment
of metastatic squamous non-small cell lung cancer
(NSCLC) that has progressed on or after platinum-based
chemotherapy. It is the second PD-1 inhibitor to
be marketed in the US after pembrolizumab (Keytruda),
and the first to be approved for treatment of NSCLC.
Safety of Long-Term PPI Use
The Medical Letter on Drugs and Therapeutics • Aug 14, 2017 (Issue 1527)
, are one of
the most commonly prescribed classes of drugs in
the US. All PPIs are similarly effective ...
Proton pump inhibitors (PPIs), which are used for
treatment of gastroesophageal reflux disease (GERD)
and for prevention of upper gastrointestinal adverse
effects caused by NSAIDs and aspirin, are one of
the most commonly prescribed classes of drugs in
the US. All PPIs are similarly effective and generally
well tolerated, but their long-term use has been
associated with a number of safety concerns.
Recommendations addressing these concerns have
recently been published.
Addendum: Aducanumab (Aduhelm) for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • Jul 26, 2021 (Issue 1629)
. Int J Cancer 2018; 143:1305.
3. FDA, HHS. Sunscreen drug products for over-the-counter human
use ...
In June 2021, the FDA approved the IV amyloid beta-directed
monoclonal antibody aducanumab (Aduhelm) for treatment
of Alzheimer’s disease. The approval did not restrict use of
the drug to patients with mild cognitive impairment or mild
dementia, which was the population enrolled in the clinical
trials. Now, Biogen, with the permission of the FDA, has made
an addition to the labeling of the drug that says: Treatment with
Aduhelm should be initiated in patients with mild cognitive
impairment or mild dementia stage of disease, the population
in which treatment was initiated in clinical...
Vaccines for Travelers
The Medical Letter on Drugs and Therapeutics • Nov 19, 2018 (Issue 1560)
vaccine, may benefit from an extra priming dose; in a
study in adults with drug-induced immunosuppression ...
Persons planning to travel outside the US should be
up to date on routine vaccines and, depending on their
destination, duration of travel, and planned activities,
may also receive certain travel-specific vaccines.
Tickborne encephalitis and dengue vaccines, which
are not available in the US, are reviewed in a separate
article available online. Detailed advice for travel to
specific destinations is available from the Centers for
Disease Control and Prevention (CDC) at www.cdc.gov/travel/destinations/list. Recommendations for
administration of vaccines as part of routine...